675 Charles E Young Dr S
BOX 957019, MRL Rm 1240
Los Angeles, CA 90095
|Associate Director, UCLA Center for Systems Biomedicine, UCLA GI Fellowship Training Program|
|Assistant Professor In-Residence, Digestive Diseases/Gastroenterology|
Dr. Padua received his undergraduate education at the University of Chicago, majoring in biological chemistry and graduating with honors. His interest in the medical sciences led him to apply to the MD/PhD program at Cornell University. For his graduate work, he joined the lab of Dr. Joan Massagué at Memorial Sloan-Kettering Cancer Center and investigated the role of TGF-beta signaling in breast cancer metastasis. After earning his PhD, Dr. Padua completed his medical degree at the Weill Cornell Medical College. Following medical school, he joined the internal medicine residency program at UCLA and is board-certified by the American Board of Internal Medicine. Dr. Padua pursued his interest in gastroenterology and completed the fellowship program with the Vatche and Tamar Manoukian Division of Digestive Diseases at UCLA. He is a member of the UCLA Specialty Training and Advanced Research (STAR) program, post-doctoral track, and served as a co-chief fellow. During fellowship, Dr. Padua’s research led him to investigate the role of long non-coding RNA in inflammatory bowel disease in the lab of Dr. Charalabos Pothoulakis. Using an array of new technologies, this work has uncovered novel functions for previously uninvestigated portions of the genome as they relate to inflammatory bowel disease.
Dr. Padua joined the digestive diseases faculty at UCLA in 2016 with plans to pursue both basic science research and clinical gastroenterology. In 2017, he was appointed one of the associate program directors for the UCLA Gastroenterology Fellowship and will work closely with the fellows during their training. More recently, he was appointed the associate director for the Center of Systems Biomedicine. His research interests include cell-signaling mechanisms in complex biological disorders such as inflammatory bowel disease and colorectal cancer. Utilizing high-throughput technologies, he hopes to uncover new therapeutic and diagnostic tools for these clinical diseases.